Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

laboratorios casen-fleet s.l.u - natrii dihydrophosphas+natrii hydrophosphas - solutie rectala - 21,4 g + 9,4 g

Uniunea Europeană - română - EMA (European Medicines Agency)

zoetis belgium sa - synthetic peptide analogue of gnrf conjugated to diptheria toxoid - imunologii pentru suidae - male pigs (from 8 weeks of age); female pigs (from 14 weeks of age) - male pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of testicular function. for use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. un alt factor care contribuie la mâncarea de mistreți, skatole, poate fi de asemenea redus ca efect indirect. comportamentele agresive și sexuale (de montare) sunt de asemenea reduse. female pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).

Uniunea Europeană - română - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - pui - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Uniunea Europeană - română - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - pui - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

micro labs ltd - metamizoli de sodiu + pitofenonum + fenpiverini bromidum - solutie injectabila - 2500 mg + 10 mg + 0,1 mg/

Uniunea Europeană - română - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - imunosupresoare - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriazică arthritiscosentyx, singur sau în asociere cu metotrexat (mtx), este indicat pentru tratamentul artritei psoriazice active la pacienții adulți, atunci când răspunsul la precedenta modificare a bolii anti-reumatice droguri (marmb) a fost terapia inadecvată. spondilartrită axială (axspa)spondilita anchilozantă (ca, radiografic spondilartrită axială)cosentyx este indicat pentru tratamentul de spondilită anchilozantă activă la adulți care au răspuns inadecvat la terapia convențională. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Uniunea Europeană - română - EMA (European Medicines Agency)

bayer animal health gmbh - imidacloprid, moxidectin - produse antiparazitare, insecticide și repellente - dogs; cats; ferrets - dogsfor câini infestați sau expuși riscului de infecții parazitare mixte:tratamentul și prevenirea infestării cu purici (ctenocephalides felis),tratamentul cu păduchi malofagi (trichodectes canis),tratarea râiei auriculare (otodectes cynotis), râiei sarcoptice (determinata de sarcoptes scabiei var. canis), demodecia (cauzate de demodex canis),prevenirea dirofilariozei cardiace (larve l3 și l4 de dirofilaria immitis),tratamentul de microfilarii circulante (dirofilaria immitis),tratamentul dirofilariozei cutanate (adult etape de dirofilaria repens)prevenirea dirofilariozei cutanate (larve l3 de dirofilaria repens),reducerea de microfilarii circulante (dirofilaria repens),prevenirea angiostrongylosis (larve l4 și adulți imaturi de angiostrongylus vasorum),tratamentul infestării cu angiostrongylus vasorum și crenosoma vulpis,prevenirea spirocercosis (spirocerca lupi),tratamentul eucoleus (syn. capillaria) boehmi (adulți),tratamentul ochiului worm thelazia callipaeda (adulți),tratamentul infectiilor cu nematode gastrointestinale (larve l4, adulți imaturi și adulți de toxocara canis, ancylostoma caninum și uncinaria stenocephala, adulți de toxascaris leonina și trichuris vulpis). produsul poate fi utilizat ca parte a unei strategii de tratament pentru dermatita alergică la purici (fad). catsfor pisici infestate sau expuse riscului de infecții parazitare mixte:tratamentul și prevenirea infestării cu purici (ctenocephalides felis),tratarea râiei auriculare (otodectes cynotis),tratamentul notoedric mange (notoedres cati),tratamentul pulmonari eucoleus aerophilus (syn. capillaria aerophila) (adulți),prevenirea pulmonari boala (l3/l4 larve de aelurostrongylus abstrusus),tratamentul pulmonari aelurostrongylus abstrusus (adulți),tratamentul ochiului worm thelazia callipaeda (adulți),prevenirea dirofilariozei cardiace (larve l3 și l4 de dirofilaria immitis),tratamentul infectiilor cu nematode gastrointestinale (larve l4, adulți imaturi și adulți de toxocara cati și ancylostoma tubaeforme). produsul poate fi utilizat ca parte a unei strategii de tratament pentru dermatita alergică la purici (fad). ferretsfor dihori infestați sau expuși riscului de infecții parazitare mixte:tratamentul și prevenirea infestării cu purici (ctenocephalides felis),prevenirea dirofilariozei cardiace (larve l3 și l4 de dirofilaria immitis).

Uniunea Europeană - română - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - west nile canarypox virus recombinat (vcp2017 virus) - produsele imunologice pentru ecvidee, cal, produsele imunologice - cai - imunizarea activă a cailor de la vârsta de cinci luni împotriva bolii west nile prin reducerea numărului de cai viraemici. dacă sunt prezente semne clinice, durata și severitatea lor sunt reduse.

Uniunea Europeană - română - EMA (European Medicines Agency)

merck sharp & dohme b.v. - pembrolizumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; endometrial neoplasms - agenți antineoplazici - melanomakeytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. keytruda as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with stage iib, iic, or with stage iii melanoma and lymph node involvement who have undergone complete resection. non small cell lung carcinoma (nsclc)keytruda as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum based chemotherapy (for selection criteria, see section 5. keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 50% tumour proportion score (tps) with no egfr or alk positive tumour mutations. keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non squamous non small cell lung carcinoma in adults whose tumours have no egfr or alk positive mutations. keytruda, in combination with carboplatin and either paclitaxel or nab paclitaxel, is indicated for the first line treatment of metastatic squamous non small cell lung carcinoma in adults. keytruda  as monotherapy is indicated for the treatment of locally advanced or metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 1% tps and who have received at least one prior chemotherapy regimen. pacienții cu egfr sau alk pozitiv de tumoră mutații ar trebui să, de asemenea, au primit terapie vizate înainte de a primi keytruda. classical hodgkin lymphoma (chl)keytruda as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical hodgkin lymphoma who have failed autologous stem cell transplant (asct) or following at least two prior therapies when asct is not a treatment option. urothelial carcinomakeytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum containing chemotherapy. keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin containing chemotherapy and whose tumours express pd l1 with a combined positive score (cps) ≥ 10. head and neck squamous cell carcinoma (hnscc)keytruda, as monotherapy or in combination with platinum and 5 fluorouracil (5 fu) chemotherapy, is indicated for the first line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a cps ≥ 1. keytruda as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a ≥ 50% tps and progressing on or after platinum containing chemotherapy. renal cell carcinoma (rcc)keytruda, in combination with axitinib, is indicated for the first line treatment of advanced renal cell carcinoma in adults. keytruda  as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions (for selection criteria, please see section 5. microsatellite instability high (msi-h) or mismatch repair deficient (dmmr) cancerscolorectal cancer (crc)keytruda as monotherapy is indicated for theadults with msi-h or dmmr colorectal cancer in the following settings:first line treatment of metastatic microsatellite instability high (msi h) or mismatch repair deficient (dmmr) colorectal cancer in adults;treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine based combination therapy.  non-colorectal cancerskeytruda as monotherapy is indicated for the treatment of the following msi h or dmmr tumours in adults with:advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation;unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. oesophageal carcinomakeytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or her-2 negative gastroesophageal junction adenocarcinoma, in adults whose tumours express pd l1 with a cps ≥ 10. triple negative breast cancer (tnbc)keytruda, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence. keytruda, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express pd l1 with a cps ≥ 10 and who have not received prior chemotherapy for metastatic disease. endometrial carcinoma (ec)keytruda, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation. cervical cancerkeytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express pd l1 with a cps ≥ 1. gastric or gastro-oesophageal junction (gej) adenocarcinomakeytruda, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic her2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express pd-l1 with a cps ≥ 1.

Uniunea Europeană - română - EMA (European Medicines Agency)

pfizer europe ma eeig - neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid - meningită, meningococică - vaccinuri - nimenrix este indicat pentru imunizarea activă a persoanelor de la vârsta de 6 săptămâni împotriva bolilor meningococice invazive cauzate de grupul neisseria meningitidis a, c, w-135 și y.